Citations

Clear

1446 citation(s) found for "Howard, F".

Historical outcomes for patients with stage IA NLPHL: Global NLPHL One Working Group retrospective analyses
Flerlage, Jamie E. , Eichenauer, Dennis A. , Fuchs, Michael, Hartmann, Sylvia , Eich, Hans Theodor, Savage, Kerry J. , Skinnider, Brian, Akhtar, Saad , Steiner, R., Milgrom, Sarah A., Vega, Francisco, Alomari, Mohammed , Zhang, Xiaoyin , Collins, Graham P., Advani, Ranjana H, Kumar, Priyadarshini , Wirth, Andrew, Tsang, Richard, Smith, SD, Hendrickson, Peter G. , Hopkins, David, McKay, Pamela, Ng, Andrea K. , Koenig, Julie L. , Sakthivel, Gukan, Baron, Jonathan A, Roberts, Kenneth B. , Gao, Sarah, Alkendi, Jalila , Rahbi, Nasser Al, Balogh, Alexander George, Ricardi, Umberto, Sridhar, Akshay, Torka, Pallawi , Specht, Lena , Silva, Ravi De , Shah, Nimish, Osborne, Wendy , Henry, Michael, Chang, Isabela , Halperin, Daniel, Miall, Fiona , Brady, J.L. , Mikhaeel, G., Brennan, Bernadette , Penn, Anthony, Reeves, Marie, Terezakis, Stephanie A, Pepa, R Della, Picardi, Marco, Kirova, Youlia, Fergusson, Paige, Hawkes, Eliza A. , Lee, Denise , Ku, Matthew , Hamad, Nada, Mutsando, Howard , Tedjaseputra, Aditya , Gilbertson, Michael, Marconi, Tamara , Viiala, Nicholas , Palese, Monica , Kelly, Kara M, Borchmann, P, Hoppe, Richard T. , Advani, Ranjana H. , Hopkins, David , Baron, Jonathan , Vega, Francisco , Kumar, Priyadarshini , Dickinson, Michael , Smith, Sonali M , McKay, Pamela , Koenig, Julie , Casulo, Carla , Al Kendi, Jalila , Levis, Mario , Torka, Pallawi , Specht, Lena , De Silva, Ravindu , Pickard, Keir , Smith, Christine M , Brady, Jessica , Senchenko, Maria Anatolevna , Volchkov, Egor Vasilevich , Hoppe, Bradford S , Hawkes, Eliza , Lee, Denise , Doo, Nicole Wong , Barraclough, Allison , Cheah, Chan Yoon , Salvaris, Ross , Ku, Matthew , Hamad, Nada , Tedjaseputra, Aditya , Shankar, Ananth , Maurer, Matthew , Natkunam, Yasodha , Hoppe, Richard T , Binkley, Michael Sargent , Savage, Kerry J , Advani, Ranjana H , Hopkins, David , Baron, Jonathan , Eichenauer, Dennis A , Flerlage, Jamie E , Fuchs, Michael, Eich, Hans Theodor, Hodgson, David C. , Skinnider, Brian, Rauf, M. Shahzad , Maghfoor, Irfan , Pinnix, Chelsea C. , Alomari, Mohammed, Collins, Graham P. , Dickinson, Michael , Tsang, Richard , Prica, Anca A. , Major, Ajay , Kelsey, Chris R. , Constine, Louis S , Casulo, Carla , Plastaras, John Peter , Balogh, Alexander G., Levis, Mario , Ricardi, Umberto , Sridhar, Akshay, Shah, Nimish , Pickard, Keir , Blazin, Lindsay , Henry, Michael, Smith, Christine M. , Hoppe, Bradford S. , Talaulikar, Dipti , Pepa, Roberta Della , Picardi, Marco , Kirova, Youlia , Northend, Michael , Doo, Nicole Wong , Barraclough, Allison , Opat, Stephen , Cheah, Chan Y. , Hamad, Nada , Gilbertson, Michael , Maurer, Matthew J. , Natkunam, Yasodha , Kelly, Kara M. , Borchmann, Peter , Binkley, Michael S.

Mayo Clinic

Blood Advances | April 14, 2026 | Volume: 10 | Issue: 15 | Pages: 5338-5347

10.1182/bloodadvances.2026020012 | PMID 41979337 Get It

Abstract We evaluated outcomes by management type for patients with stage IA nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) in the Global NLPHL One Working Group retrospective database of 2243 patients with stages I to IV disease diagnosed from 1992 to 2021 at 38 international institutions. A total of 779 patients had stage IA disease with median age of 35 years (range, 3-89) and median follow-up of 6.1 years. The 6-year progression-free survival (PFS) and overall survival were 86.3% and 97.7%, respectively. Outcomes were analyzed for the 2 groups: complete resection and unresected disease. Patients with a complete resection and observation alone (n = 99) had a 6-year PFS of 65.5% vs 90.5% for those who received radiotherapy (RT) (n = 53). Patients with unresected disease (n = 627; 80.5%) had a 6-year PFS of 62.0% for rituximab alone (n = 31), 89.6% for RT alone (n = 325), 76.8% for ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) alone (n = 40), and 94.3% for ABVD plus RT (n = 130). A total of 127 patients relapsed (16.3%), of which 25 (19.7%) had transformation. Our analysis suggests the following: (1) RT improves the PFS in patients with completely resected disease; (2) rituximab or ABVD alone does not appear to achieve a durable response; and (3) chemotherapy was not observed to add additional PFS benefit when used in combination with RT. Thus, for stage IA NLPHL, RT alone is likely sufficient for definitive treatment.
Skin Manifestations of Hereditary Cancer Syndromes: A Clinicopathologic Review
Colbert, Michelle D. , Mittal, Setu , Ghebrehiwet-Kuflom, Johanna, Mohandesi, Nessa A., Aghazadeh, Nessa , Aghazadeh Mohandesi, Nessa , Mittal, Setu , Lehman, Julia S. , Erickson, Lori A.

Mayo Clinic

Advances in Anatomic Pathology | April 14, 2026 | Volume: 33 | Issue: 4 | Pages: 304-330

10.1097/pap.0000000000000534 | PMID 41979101 Get It

The focus of this review is the clinical and pathologic presentations of hereditary cancer syndromes with cutaneous manifestations, with the goal of providing a reference for the multidisciplinary care teams involved in the diagnosis and management of these conditions. Advancements in genomics have led to newly recognized syndromes and a deeper understanding of established syndromes. We focus on those with the most relevant cutaneous manifestations. Clinical and histopathologic images provide visual context for these findings, many of which are rare. We summarize the established literature and incorporate new research and noteworthy case reports.
Real-World Outcomes of Transcatheter Tricuspid Valve Replacement
Makkar, R R, Gupta, A, O’Neill, Brian P., Lalani, Christina , Sharma, Rahul P., Yadav, Pradeep, Frisoli, Tiberio M., Thourani, Vinod, Eleid, Mackram F., Lee, James, Babaliaros, Vasilis C., Haeffele, Christiane , Bajwa, Tanvir , Flueckiger, Peter, Cubeddu, Robert J., Davidson, Laura J., Padang, Ratnasari , Spinetto, Pedro Villablanca, Narang, Akhil , Williams, Mathew, Gleason, Patrick, Tang, Gilbert H. L., Khera, Sahil , Vavalle, John P., Byku, Isida , Depta, Jeremiah P., Garcia, Santiago, Kapadia, Samir, Zajarías, Alan , Chanin, Jake, Kodali, Susheel K., Herrmann, Howard C., Morse, M. Andrew, Petrossian, George , Sivak, Joseph A. , Hahn, Rebecca T., Song, Yang, Leon, M.B., Yeh, Robert W., Davidson, C, Haeffele, Christiane , Makkar, Raj , Gupta, Aakriti , O’Neill, Brian Patrick , Sharma, Rahul P., Yadav, Pradeep , Frisoli, Tiberio , Thourani, Vinod H. , Makar, Moody M. , Eleid, Mackram F. , Lee, James, Babaliaros, Vasilis , Flueckiger, Peter B. , Davidson, Laura J., Allaqaband, Suhail Q. , Williams, Mathew R., Gleason, Patrick T. , Tang, Gilbert H.L. , Vavalle, John P. , Depta, Jeremiah P , Garcia, Santiago A. , Kapadia, Samir , Kodali, Susheel , Herrmann, Howard C. , Morse, M. Andrew M. , Hahn, Rebecca T , Song, Yang, Yeh, Robert W. , Davidson, Charles J.

Mayo Clinic

JAMA | April 13, 2026 | Volume: 335 | Issue: 18 | Pages: 1606

10.1001/jama.2026.3446 | PMID 41973411 Get It

Importance Transcatheter tricuspid valve replacement (TTVR) demonstrated superior outcomes over medical therapy in patients with severe tricuspid regurgitation (TR) in the Edwards EVOQUE Transcatheter Tricuspid Valve Replacement: Pivotal Clinical Investigation of Safety and Clinical Efficacy Using a Novel Device II (TRISCEND II) randomized clinical trial, and received regulatory approval in the US in 2024. Contemporary real-world data on its effectiveness and safety remain limited. Objective To evaluate 30-day clinical, echocardiographic, and health status outcomes of TTVR in real-world use. Design, Setting, and Population Retrospective cohort study of all consecutive patients who underwent TTVR in the US from February 2024 through March 2025 in the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. Patients had symptomatic, severe TR despite optimal medical therapy and TTVR was deemed appropriate by a heart team. Statistical analysis was conducted from September 2025 to February 2026. Exposure Device-enabled TTVR. Main Outcomes and Measures Thirty-day event rates (all-cause death, stroke, bleeding, new cardiac implantable electronic device [CIED] implantation, heart failure hospitalizations), TR reduction, and changes in health status (New York Heart Association [NYHA] functional class and Kansas City Cardiomyopathy Questionnaire Overall Summary [KCCQ-OS] score) are reported. Subgroup analyses examined the impact of baseline CIED status on outcomes. Results Among 1034 attempted procedures at 82 centers (mean [SD] age, 77.1 [10.6] years; 69.1% female; 73.2% NYHA functional class III/IV), a valve was successfully implanted in 1017 patients (98.4%). Mild or less TR was achieved in 98.4% of patients post procedure and in 97.7% at 30 days. At 30 days, all-cause mortality was 3.1%; stroke, 0.2%; bleeding, 7.9%; new CIED, 15.9% in CIED-naive patients; and heart failure hospitalization, 3.1%. There were significant improvements in NYHA functional class (class I/II, 82.7%; P < .001) and mean KCCQ-OS score (22.4 points; P < .001) from baseline to 30 days. There were no significant differences in 30-day mortality ( P = .47), heart failure hospitalization ( P > .99), and functional outcomes ( P = .55) when patients were stratified by baseline CIED status. Conclusions and Relevance Early US real-world experience with TTVR confirms safety and effectiveness in patients with severe TR. Thirty-day outcomes are consistent with the TRISCEND II pivotal trial, demonstrating acceptable safety, near-complete TR elimination, and significant health status improvements in an older, comorbid population. Rates of new CIED implantation and bleeding were lower than randomized clinical trial experience.
Development of a standard definition of ‘no-option’ and ‘poor-option’ for revascularization in chronic limb-threatening ischemia
Fabiani, Mario Alejandro , Berg, Jos C van den, Torre, Oscar A De la, Verastegui, Alfredo , Dua, Anahita, Alexandrescu, Vlad Adrian, Baadh, Amanjit S. , Bahaa, Nasr, Carvajal, Juan Guillermo Barrera, Beasley, Robert , Bisdas, Theodosios, Blessing, Erwin , Bonvini, Stefano, Brodmann, Marianne, Cabral, Gonçalo, Cancellieri, Roberto, Casini, Andrea , Chandra, Venita , Chisci, Emiliano, Chohan, Omar, Choke, Edward, Chong, Patrick, Clerici, Giacomo , Coscas, Raphaël, Costantino, Del Giudice, D'Oria, Mario, Davies, Robert, Donato, Gianmarco de , Vries, Jean-Paul de , Río-Solá, M.L. del, Deloose, Koen , Dhand, Sabeen , Díaz-Sandoval, Larry J, Falcone, Gianmarco , Fanelli, Fabrizio , Cardona, Lucas Ferrer, Garg, Karan, Giuffrida, Stefania, Gouëffic, Yann, Goverde, Peter , Henao, Esteban, Vegas, Diego Jorge Herrera, Hinchliffe, Robert, Hoballah, Jamal J. , Howard, Dominic, Huasen, Bella , Iida, Osamu, Katsanos, Konstantinos, Kolh, Philippe, Korosoglou, Grigorios, Lecis, Alexandre, Leopoldo, Marine, Lessne, Mark L. , Lichtenberg, Michael, Lobato, Marta , Loreni, Giorgio, Madassery, Kumar, Manzi, Marco, Maene, Lieven, Maresch, Martin, Trabal, Jorge Martinez, Mathews, S Jay, Michael, Siah, J, Bosiers Michel, Migliara, Bruno , Mills, Joseph, Miserlis, Dimitrios , Montero-Baker, Miguel, Alvarez, Luis Morelli, Morgan, Robert Anthony, Mouawad, Nicolas, Moxey, Paul, Antonio, Jose, Nakama, Tatsuya , Neville, Richard, Noronen, Katariina , Palena, Mariano, Parikh, Sahil, Parlani, Gianbattista, Pasqui, Edoardo , Patel, Rafiuddin, Patel, Ashish, Perkov, Dražen , Portou, Mark James, Langhoff, Ralf , Reijnen, Michel Marinus Petrus Johannes, Roy, Trisha , Ruffino, Maria Antonella , Gúzman, Tania Sáez, Sakr, Ahmed, Santini-Domínguez, Rafael , Schmidt, Andrej, Schneider, Peter, Sheorain, Virendersingh K, Siracuse, Jeffrey, Sirvent, Marc , Sommerset, Jill , Spiliopoulos, Stavros, Spinelli, Alessio , Stavroulakis, Konstantinos, Taneva, Gergana T, Teso, Desarom , Thomas, Shannon, Torsello, Giovanni, Tummala, Venkat, Tummala, Srinivas, Twine, Christopher, Uberoi, Raman, Heuvel, Daniel Van den, Varcoe, Ramon Lee, Serrano, José Francisco Vargas, Céniga, Melina Vega de, Venermo, Maarit, Vijaynagar, Badri, Stempel, Conrad von , Voûte, Michiel Thomas, Watts, Mine, Zaefferer, Patricio, Zayed, Hany , Zeebregts, Clark J, Zola, N'Dandu, Mills, Joseph L. , Torre, O. , Verastegui, Alfredo , de la Torre, Oscar , Fabiani, Mario Alejandro , Berg, Jos C. van den , Dua, Anahita , Nasr, Bahaa , Biasi, Lukla , Bisdas, Theodosios , Brodmann, Marianne , Cabral, Gonçalo , Caradu, Caroline , Casini, Andrea , Chisci, Emiliano , Choke, E, Chong, Patrick L.E., Cioppa, Angelo , Coscas, Raphaël , Giudice, Costantino Del , D'Oria, Mario , Peruyera, Pablo Del Canto , Διαμαντόπουλος, Αθανάσιος , Díaz‐Sandoval, Larry J. , Dick, Florian , Fazzini, Stefano , Ferrer, Lucas M. , Fujihara, Masahiko , Garg, Karan , Garriboli, Luca , Genovese, Elizabeth A. , Gifford, Edward D. , Gouëffic, Yann , Gupta, Prem Chand , Vegas, Diego Herrera , Hinchliffe, Robert J. , Holden, Andrew Hugh , Isernia, Giacomo , Kolh, Philippe H. , Korosoglou, Grigorios , Krokidis, Miltiadis E. , Lichtenberg, Michael, Loureiro, Luís , Mathews, S. Jay , Bosiers, Michel Joseph , Morosetti, Daniele , Mouawad, Nicolas J. , Moxey, Paul, Neville, Richard, Palena, Luis Mariano , Parikh, Sahil, Parlani, Gianbattista, Patel, Rafiuddin, Patrone, Lorenzo , Portou, Mark J. , Pratesi, Giovanni , Rammos, Christos , Reijnen, Michel M.P.J. , Sakr, Ahmed , Schneider, Peter A. , Secemsky, Eric A. , Sheorain, Virendersingh K, Simonte, Gioele , Spiliοpoulos, Stavros , Stavroulakis, Konstantinos , Steiner, Sabine , Taneva, Gergana T. , Torsello, Giovanni , Troisi, Nicola , Twine, Christopher P. , Uberoi, Raman , Ucci, Alessandro , Heuvel, Daniel van den, Varcoe, Ramon Lee , Venermo, Maarit A. , Voûte, Michiel T., Ysa, August , Zeebregts, Clark J. , Zeller, Thomas , N'Dandu, Zola M.

Mayo Clinic

British Journal of Surgery | April 3, 2026 | Volume: 113 | Issue: 4 | Pages: No page available

10.1093/bjs/znag040 | PMID 41941595 Get It

Abstract Introduction Revascularization to prevent limb loss is not feasible or represents a very high risk in a significant proportion of patients with chronic limb-threatening ischaemia (CLTI). No standard definition currently exists to define this population of patients. The aim of this study was to develop a consensus-based, multidomain definition to improve clinical assessment and reporting of studies in people with ‘no option’ (NO) or ‘poor option’ (PO) CLTI. Methods A modified Delphi process was conducted with 164 specialists from 30 countries. Two iterative survey rounds were used to reach consensus, defined as ≥70% agreement with a score of ≥7 on a nine-point scale. Results Some 164 international vascular specialists participated in the study, averaging 19 years of experience. A multidomain framework including arterial disease anatomy, biology, risk, function, and context (ABRFC) achieved 83% consensus. A ‘desert foot’ was defined as the absence of distal arterial revascularization targets on advanced non-invasive imaging, invasive digital subtraction angiography, and at least one failed endovascular revascularization attempt (81.6% agreement). Inadequate autogenous bypass conduit was defined as the lack of usable autologous vein across all four limbs (85% agreement). Patients were classified as NO for revascularization if they present with ‘desert foot’, prohibitive medical risk, a non-functional limb, or in those patients who refused arterial revascularization. PO revascularization patients combined factors such as severe infection, lack of autologous vein, or treatment non-compliance (72.1% agreement). Conclusion This consensus study established a structured, expert-validated definition of no option or poor option for revascularisation of patients with CLTI. The multidomain ABRFC framework provides a foundation for standardized clinical assessment, trial design, and future guideline development.
American Society of Breast Surgeons, Society of Breast Imaging, and College of American Pathology 2025 Guidelines for the Management of Infectious and Inflammatory Lesions of the Breast
Mitchell, Katrina B. , Snider, Howard C., Allison, Kimberly H. , Pass, Helen A. , Boolbol, Susan K., Johnson, Nathalie , Yao, Katharine , Valente, Stephanie A. , Fowler, Amy M. , Boughey, Judy C.

Mayo Clinic

JAMA Surgery | April 1, 2026 | Volume: 161 | Issue: 6 | Pages: 637

10.1001/jamasurg.2026.0613 | PMID 41920556 Get It

Importance The management of infectious and inflammatory lesions of the breast remains controversial. The expert panel focused on management recommendations for 3 of the most common infectious breast conditions, as very few evidence-based guidelines for the management of these conditions exist. Observations Clinicians should distinguish between infectious and noninfectious lactational mastitis (LM) because the former often requires interventions whereas the latter requires supportive care only. Patients with infectious LM often have thick fluid collections that are not amenable to aspiration and usually require a stab incision with drain placement (but no packing) to resolve the infection. Operative drainage is only required if the patient cannot tolerate an office procedure. If a phlegmon is present, antibiotics should be prescribed for at least 10 days. The diagnosis of granulomatous mastitis (GM) requires pathology confirmation with characteristic findings on core biopsy. Cystic neutrophilic granulomatous mastitis (CNGM) is a specific form of GM associated with a granulomatous reaction to Corynebacterium infection and should be empirically treated with doxycycline. For patients without findings characteristic of CNGM and no other associated bacterium identified, there is no role for empiric antibiotic use. Granulomatous mastitis cases often recur and can take up to 18 months to resolve. Patients who have GM cases with worsening symptoms should be treated with repeated intralesional steroid injections; surgical excision or repeated aspirations should be avoided. Cases refractory to intralesional steroid injection may require oral steroids or even advanced biologic agents such as methotrexate or azathioprine. Periductal mastitis with squamous metaplasia of lactiferous ducts (PDM-SMOLD) is a distinct entity from other periductal mastitis cases that can present with recurrent abscesses and should be treated with antibiotics and aspiration for fluid collections. Operative excision for PDM-SMOLD is required for those patients who present with a fistula or recurrent episodes typically using a radial incision to remove the diseased ducts within and below the nipple. Conclusions and Relevance Evidence-informed, consensus-, and expert opinion–based guidelines for the management of infectious and inflammatory conditions of the breast were developed. Clinicians can use these guidelines to appropriately manage these conditions for which clinical care often varied in the past.
CNSC-02. Investigating the Evolution of Neuron-Glioma Circuit Dynamics
Keough, Michael B. , Jenkins, Elise P. W. , Middya, Sagnik , Shamardani, Kiarash , Malacon, Karen , Stroud, Jake Patrick , Monje, Michelle

Mayo Clinic

Neuro-Oncology Pediatrics | March 12, 2026 | Volume: 1 | Issue: Supplement_1 | Pages: No page available

10.1093/neuped/wuaf001.021 Get It

Abstract Pediatric high-grade gliomas (pHGG) are aggressive primary brain neoplasms with a dismal prognosis, making them the leading cause of brain tumor-related deaths in children. pHGGs occur in specific anatomical locations at specific ages underscoring their origin in neurodevelopment and the critical importance of the brain tumor microenvironment. Many pHGGs originate from oligodendroglial precursor cells (OPC) and, like OPCs, neuronal activity promotes pHGG proliferation. Neuronal activity drives pHGG growth through the secretion of activity-regulated mitogens and electrochemical communication with pHGG cells that integrate into neural circuits. In turn, pHGG increases neuronal excitability and remodels functional neural circuits. The interconnected network of glioma cells and neurons is fundamental to pHGG progression. We developed a two-color in vivo imaging method to study neuron-glioma cell interactions over time in freely behaving mice enabling us to record the frequency, pattern, and synchronicity of calcium transients in neurons, glioma cells, and their coactivity, giving us a comprehensive view of the changes in neuron-glioma circuit dynamics over time. Our imaging paradigm offers a unique ability to study neuron-glioma interactions at the systems level. We have observed increasing neuronal activity and synchronicity throughout the disease. We have also observed that different gliomas exhibit unique patterns of calcium transients and show increased levels of activity and synchronicity as the tumor progresses. We verified our findings through longitudinal in vivo local field potential recordings, finding an increase in all power bands, especially in high-gamma activity over time. Using single nuclei RNA sequencing of mice harboring murine H3K27M-­altered DMG, we observed gene expression changes indicating an increase in synaptogenesis and axonogenesis processes in glioma-associated neurons. Performing in vitro neurite outgrowth assays, we observed increased axonogenesis in hiPSC-derived neurons in the presence of pHGGs compared to other neurons, confirming our snRNA-seq findings. Based on this data, we hypothesize that as gliomas progress, the neuron-glioma malignant circuitry evolves through synaptogenesis and axonogenesis to promote glioma progression.
Patient‐reported outcomes in NRG Oncology RTOG 1010: Phase 3 trial evaluating the addition of trastuzumab to trimodality treatment of HER2 overexpressing esophageal adenocarcinoma
Kachnic, Lisa A. , Moughan, Jennifer, Hong, Theodore S. , Haddock, Michael G. , Tahir, Naeem, Yoon, Harry H. , Diaz, Dayssy A. , Seaward, Samantha A. , Lominska, C.E. , O’Brien, Paul E. , Chen, Yuhchyau , Salo, J., CHRISTIE, ALFRED D., Aljumaily, R., Gore, Elizabeth , Winter, K., Safran, Howard P., Movsas, Benjamin , Seaward, Samantha A , Lominska, Christopher E , Kachnic, Lisa A , Anderson, Carryn M. , Salo, Jonathan C. , Dorth, Jennifer A. , Aljumaily, Raid, Safran, Howard

Mayo Clinic

Cancer | March 11, 2026 | Volume: 132 | Issue: 6 | Pages: No page available

10.1002/cncr.70345 | PMID 41808581 Get It

Abstract Background NRG/RTOG 1010 evaluated trastuzumab added to trimodality therapy for HER2+ localized esophageal adenocarcinoma (EAC) management. Secondary PRO objectives assessed improvement in the FACT‐Esophageal Cancer Subscale (ECS), version 4, with trastuzumab, and if improved ECS correlated with pathologic complete response (pCR). Methods Patients were randomized to weekly paclitaxel/carboplatin/radiation (chemoradiation, CRT) followed by surgery ± trastuzumab (CRT + Tras). Disease‐free survival (DFS) was the primary end point. The projected PRO sample size of 158 patients, based on an 80% participation rate of the DFS primary endpoint sample size of 197 HER2+ patients, would provide ≥ 89% power to detect ≥25% increase in the proportion of CRT + Tras patients with ECS improvement from baseline to 6–8 weeks post‐CRT; one‐sided α = 0.05, using a χ 2 test. Improvement in ECS and its swallowing index (SI) and eating index (EI) was defined as 5‐, 2‐, and 2‐point increases, respectively, from baseline to 6–8 weeks post‐CRT. Univariate logistic regression was assessed if pCR was associated with improved ECS. Results From 2010 to 2015, 203 HER2+ patients were randomized and 194 were eligible. Of 171 PRO consenting patients, the ECS was completed by 162 (95%) at baseline, 108 (64%) 6–8 weeks, 82 (49%) 1 year, and 55 (33%) at 2 years. The proportion of patients with an improvement in 6–8 weeks ECS was higher on the CRT + Tras arm (46% vs. 38%), although not significantly different ( p = .39). There was no correlation between pCR and ECS scores at 1 year, with 39% and 37% of pCR and non‐pCR patients, respectively, having improved 1‐year ECS scores. Conclusions The addition of trastuzumab to CRT for localized HER2+ EAC did not improve PROs.
Miniprotein inhibitors of the Staphylococcus aureus efflux transporter NorA
Mishra, Priyanka, Chazin-Gray, Adam, Lamon, Gaëlle , Kim, David E. , Baker, David, Traaseth, Nathaniel J. , Kim, David , Chazin-Gray, Adam M. , Baker, David

Mayo Clinic

No container title available | March 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.03.05.709893 | PMID 41847033 Get It

Abstract Multidrug efflux pumps transport antibiotics across the cellular membrane resulting in resistance conferred to the host organism. Efflux pump inhibitors (EPIs) potentiate the efficacy of antibiotics by blocking drug efflux and hold promise as adjuvant therapeutics in the fight against multidrug resistant pathogenic bacteria. A hurdle in the field has been the lack of selectivity of small molecule EPIs which often display off-target toxicity due to non-specific binding. To tackle this specificity challenge, we aimed to maximize an inhibitor’s binding surface area to efflux pumps by designing miniprotein EPIs using computational protein design and an E. coli co-expression assay to screen inhibition in cells. We used S. aureus NorA as a model efflux transporter since it confers drug resistance to fluoroquinolones, puromycin, and other cytotoxic compounds. Starting from a focused miniprotein library of only 86 members, we identified inhibitors in the screen that blocked NorA transport under active efflux conditions in vitro . Our most promising inhibitor I-23 was validated by solving a cryo-EM structure of the miniprotein in complex with NorA, which stabilized the transporter in the outward-open conformation. I-23 has a ferredoxin-like fold with one of its β-hairpins inserted into the substrate binding pocket of NorA and other parts of the globular fold occupying the shallow pocket and making extensive intermolecular contacts with NorA. An arginine residue on the tip of the hairpin loop was positioned near an anionic patch required for NorA antibiotic efflux. The identified structural motifs in this work could be employed to explore the molecular properties of peptidoglycan penetration; full realization of the therapeutic potential of the designed miniprotein inhibitors will require determining the principles for facilitating passage of ∼7 to 8 kDa miniproteins across the peptidoglycan bacterial cell wall.
Filler thriller: Complete resolution of a pair of delayed-onset nodules with hyaluronidase
Cirelli, Michael A. , Eells, Annica Cooper, Donovan, Maggie, Howard, Brittany E. , Donovan, Maggie R. , Eells, Annica C.

Mayo Clinic

Journal of Cutaneous and Aesthetic Surgery | March 5, 2026 | Issue: No issue available | Pages: 1-4

10.25259/jcas_255_2025 Get It

Granulomatous inflammation is a rare but known filler-related complication that may present similarly to an active infectious process with pain, swelling, and erythema. This study describes hyaluronic acid filler-related delayed-onset nodule formation in a pair of 44-year-old and 56-year-old females who were ineffectively treated with numerous attempts of antibiotic regimens, incision and drainage (I&D) procedures, and low-dose hyaluronidase across several months despite multiple negative microbial cultures. After initiation of hyaluronidase therapy dosed to filler-related vascular occlusion guidelines, complete resolution of symptoms was achieved in both patients. These cases emphasize the relevance of considering delayed-onset nodules in the differential for filler complications that are culture-negative and unresponsive to antibiotic treatment and I&D. We propose complete dissolution with higher dosage hyaluronidase as a safe and effective treatment modality with respect to the current lack of defined guidelines for treating this complication.
Structural Basis for C 8 methylation of 23S ribosomal RNA by Cfr
Esakova, Olga , Jung, James , Lee, Hyunwook , Cho, Sung Hyun , Alumasa, John N., Schwalm, Erica L. , Bauerle, Matthew , Hafenstein, Susan , Yu, Zhiheng, Booker, Squire J. , Esakova, Olga A , Alumasa, John , Hafenstein, Susan L , Booker, Squire J , Grove, Tyler L. , Yu, Zhiheng

Mayo Clinic

No container title available | March 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.02.27.707579 | PMID 41867798 Get It

Abstract Cfr methylates C 8 of adenosine 2503 (A2503) in 23 S ribosomal RNA (rRNA) and will also methylate C 2 of A2503 after methylating C 8 . C 8 methylation confers resistance to more than five classes of clinically used antibiotics, highlighting it as a worrisome mechanism of antibiotic resistance. Here, we report the structure of Cfr, determined by cryogenic electron microscopy (Cryo-EM). Despite its small size (∼36 kDa), we exploit a transient protein–RNA crosslink that forms during catalysis, which requires Cys105 to resolve. Using a Cfr Cys105Ala variant and an 87-nucleotide strand of rRNA, we isolate the crosslinked species and determine its structure to 3.0 Å resolution. Notably, the 87-mer rRNA adopts an L-shaped conformation characteristic of tRNAs, rather than the conformation it assumes in the ribosome. One Sentence Summary Cryo-EM structure of Cfr, a radical S-adenosylmethionine methylase that confers antibiotic resistance